Literature DB >> 8799222

Teboroxime is a marker of reperfusion after myocardial infarction.

L I Heller1, B J Villegas, C P Reinhardt, S T Dahlberg, R Marcel, J A Leppo.   

Abstract

BACKGROUND: It has been shown that serial teboroxime imaging can rapidly assess coronary perfusion in viable myocardial distributions. However, the myocardial uptake of teboroxime after reperfusion of acutely infarcted myocardium has not been critically evaluated. The study object was to assess whether teboroxime uptake in acutely infarcted myocardium is linearly related to blood flow. METHODS AND
RESULTS: Seventeen New Zealand rabbits underwent occlusion of the left circumflex coronary artery for 1 hour. The animals were reperfused for 2 hours and, just before they were killed, teboroxime was injected. The infarct was delineated by triphenyltetrazolium chloride staining. Normalized blood flow and myocardial teboroxime distribution in the infarcted myocardium was determined by gamma well counting. Ex vivo planar images of the left ventricle were also acquired. Transmural myocardial infarction was documented in all 17 rabbits. The mean infarct size +/- one standard deviation was 25.5% +/- 10.7% (range, 11.9% to 43.3%). There was a direct linear relationship between normalized reperfusion flow and myocardial teboroxime distribution in the infarct zone (r = 0.91). A direct linear relationship between defect size and normalized infarct zone reperfusion was also evident on the ex vivo planar studies (r = 0.70).
CONCLUSION: This study shows that the initial uptake of teboroxime in acutely infarcted myocardium is linearly related to blood flow. Teboroxime has properties that are well suited for the early evaluation of infarct zone perfusion.

Entities:  

Mesh:

Substances:

Year:  1996        PMID: 8799222     DOI: 10.1016/s1071-3581(96)90018-5

Source DB:  PubMed          Journal:  J Nucl Cardiol        ISSN: 1071-3581            Impact factor:   5.952


  30 in total

1.  Trial of tissue plasminogen activator for mortality reduction in acute myocardial infarction. Anglo-Scandinavian Study of Early Thrombolysis (ASSET).

Authors:  R G Wilcox; G von der Lippe; C G Olsson; G Jensen; A M Skene; J R Hampton
Journal:  Lancet       Date:  1988-09-03       Impact factor: 79.321

2.  Thallium redistribution in dogs with severe coronary artery stenosis of fixed caliber.

Authors:  G M Pohost; R D Okada; D D O'Keefe; H Gewirtz; G Beller; H W Strauss; J S Chaffin; J Leppo; W M Daggett
Journal:  Circ Res       Date:  1981-03       Impact factor: 17.367

3.  The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings.

Authors: 
Journal:  N Engl J Med       Date:  1985-04-04       Impact factor: 91.245

4.  Long-term effects of intravenous thrombolysis in acute myocardial infarction: final report of the GISSI study. Gruppo Italiano per lo Studio della Streptochi-nasi nell'Infarto Miocardico (GISSI).

Authors: 
Journal:  Lancet       Date:  1987-10-17       Impact factor: 79.321

5.  Sequential teboroxime imaging during and after balloon occlusion of a coronary artery.

Authors:  L I Heller; B J Villegas; B H Weiner; B A McSherry; S T Dahlberg; J A Leppo
Journal:  J Am Coll Cardiol       Date:  1993-05       Impact factor: 24.094

6.  Intravenous tissue plasminogen activator and size of infarct, left ventricular function, and survival in acute myocardial infarction.

Authors:  F Van de Werf; A E Arnold
Journal:  BMJ       Date:  1988-11-26

7.  A randomized trial of immediate versus delayed elective angioplasty after intravenous tissue plasminogen activator in acute myocardial infarction.

Authors:  E J Topol; R M Califf; B S George; D J Kereiakes; C W Abbottsmith; R J Candela; K L Lee; B Pitt; R S Stack; W W O'Neill
Journal:  N Engl J Med       Date:  1987-09-03       Impact factor: 91.245

Review 8.  Recombinant single-chain urokinase-type plasminogen activator during acute myocardial infarction.

Authors:  C Diefenbach; R Erbel; T Pop; D Mathey; J Schofer; C Hamm; H Ostermann; U Schmitz-Hübner; W Bleifeld; J Meyer
Journal:  Am J Cardiol       Date:  1988-05-01       Impact factor: 2.778

9.  Effect of intravenous APSAC on mortality after acute myocardial infarction: preliminary report of a placebo-controlled clinical trial. AIMS Trial Study Group.

Authors: 
Journal:  Lancet       Date:  1988-03-12       Impact factor: 79.321

10.  Thallium-201 accumulation during reperfusion of ischemic myocardium: dependence on regional blood flow rather than viability.

Authors:  R Forman; E S Kirk
Journal:  Am J Cardiol       Date:  1984-09-01       Impact factor: 2.778

View more
  5 in total

1.  Assessment of reperfusion after acute myocardial infarction: is there a role for acute technetium 99m-teboroxime imaging?

Authors:  A J Sinusas
Journal:  J Nucl Cardiol       Date:  1996 Jan-Feb       Impact factor: 5.952

2.  Theoretical model for myocardial functional characterization: application to a group of patients evaluated before and after surgical revascularization.

Authors:  L Bontemps; M Nazzi; M Gabain; O Jegaden; R Felecan; R Itti
Journal:  J Nucl Cardiol       Date:  1998 Mar-Apr       Impact factor: 5.952

3.  Planar imaging of 99mTc-labeled (bis(N-ethoxy, N-ethyl dithiocarbamato) nitrido technetium[V]) can detect resting ischemia.

Authors:  G Johnson; K N Nguyen; Z Liu; P Gao; R Pasqualini; R D Okada
Journal:  J Nucl Cardiol       Date:  1997 May-Jun       Impact factor: 5.952

4.  The effect of ischemic injury on the cardiac transport of Tc-99m N-NOET in the isolated rabbit heart.

Authors:  T A Holly; J A Leppo; M P Gilmore; C P Reinhardt; S T Dahlberg
Journal:  J Nucl Cardiol       Date:  1999 Nov-Dec       Impact factor: 5.952

5.  Myocardial clearance of technetium-99m-teboroxime in reperfused injured canine myocardium.

Authors:  David R Okada; Gerald Johnson; Robert D Okada
Journal:  EJNMMI Res       Date:  2014-08-01       Impact factor: 3.138

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.